Merck and Bayer unveil the data behind their CV ‘success,’ underwhelming the industry

Four months after Merck announced a surprise Phase III success on the heart drug they gave Bayer $1 billion for, the full data is out — and cardiologists, investors and payers are left wondering just how effective the drug really is.